Saturday, February 24, 2018
Thanks to a recent article in Time Magazine, Nicotinamide Riboside and NAD replenishment are getting a lot of attention. Because I have been taking NR for 18 months, and have been following the science closely, I will attempt to explain...
Tailwinds' Take: with nearly 140 trials underway involving Niagen, CDXC has more than its share of catalysts coming in the near future. These two new trials for for Alzheimers and CHF...two areas that have had very positive mouse trials...
One of our top picks, Chromadex shares have been under pressure over the last few months. The shares hit a high of around $7 in November, but worked their way lower, trading as low as $4.50 last week. This...
Tailwinds' Take: Revenue exceeded Company and Wall Street forecasts. Singapore launch coming in Q1. Well positioned for a huge 2018. IRVINE, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
Tailwinds' Take: yet another positive study result for what will surely become a blockbuster supplement. CDXC stock has traded well off its highs. Great time to look at it.  The supplement nicotinamide riboside (NR) – a form of vitamin B3...
Tailwinds' Take: while not unexpected, a very important win for CDXC, which takes away the biggest potential concern for the Company.  IRVINE, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age,...
Tailwinds' Take: based on their "successful", to quote the Company, launch in Hong Kong, this is probably the first of several more markets that Watsons will open up to Tru Niagen. CDXC remains on track to have a blockbuster...
As we enter the new year it is very difficult not to be optimistic...borderline exuberant. The Tailwinds Select Portfolio has been on a tear lately, closing the year with a bang. If gaining 20% in the last two months...
Tailwinds' Take: the implications of this study are potentially massive. It truly appears that NR has many positive effects and is well on its way to becoming a blockbuster supplement. No side effects, many benefits. There appears to be...
IRVINE, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that in research published in the journal Nature, Dr. Johan Auwerx showed that Alzheimer’s disease...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address